July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Selective retina therapy for macular serous retinal detachment associated with tilted disc syndrome
Author Affiliations & Notes
  • Kumiko Hirayama
    Ophthal & Visual Sciences, Osaka City Univ Grad Sch of Med, Osaka-shi, OSAKA, Japan
  • Manabu Yamamoto
    Ophthal & Visual Sciences, Osaka City Univ Grad Sch of Med, Osaka-shi, OSAKA, Japan
  • Takeya Kohno
    Ophthal & Visual Sciences, Osaka City Univ Grad Sch of Med, Osaka-shi, OSAKA, Japan
  • Dirk Theisen-Kunde
    Medical Laser Center Luebeck, Germany
  • Ralf Brinkmann
    Medical Laser Center Luebeck, Germany
    Institute of Biomedical Optics, University of Luebeck,, Germany
  • Yoko Miura
    Medical Laser Center Luebeck, Germany
    Institute of Biomedical Optics, University of Luebeck,, Germany
  • Shigeru Honda
    Ophthal & Visual Sciences, Osaka City Univ Grad Sch of Med, Osaka-shi, OSAKA, Japan
  • Footnotes
    Commercial Relationships   Kumiko Hirayama, None; Manabu Yamamoto, None; Takeya Kohno, None; Dirk Theisen-Kunde, None; Ralf Brinkmann, None; Yoko Miura, None; Shigeru Honda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5035. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kumiko Hirayama, Manabu Yamamoto, Takeya Kohno, Dirk Theisen-Kunde, Ralf Brinkmann, Yoko Miura, Shigeru Honda; Selective retina therapy for macular serous retinal detachment associated with tilted disc syndrome. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5035.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tilted disc syndrome (TDS) may be associated with a macular serous retinal detachment (SRD). However, ideal therapy for this complication is still unestablished yet to date. The purpose of this study is to investigate the effect of selective retina therapy (SRT) for macular SRD associated with TDS.

Methods : This retrospective study included 10 eyes of 9 patients (9 females), who were treated with SRT for SRD associated with TDS at the department of Ophthalmology of Osaka City University Hospital, and observed at least 12 months after treatment. The mean age was 56 years old (range 44-66). SRT laser (527 nm, 1.7 µs, 100 Hz; Medical Laser Center Lübeck, Germany) was used for treatment, and was irradiated at and around the leakage point assessed with fluorescein angiography. The changes of best corrected visual acuity (BCVA) and central macular thickness (CMT) in optical coherence tomography (OCT) were examined. The BCVA was measured by Landolt C chart and converted to logarithm of the minimum angle of resolution (logMAR) for calculation.

Results : The mean follow-up period was 24.4 months (range 12-48 months). The mean BCVA and CMT changed from 0.03 ± 0.11 and 328 ± 86 µm preoperatively to 0.08 ± 0.17 and 293 ± 99 µm at final follow-up, respectively, with no significant difference (BCVA: p=0.26, CMT: p=0.24). The SRD disappeared in 5 eyes (50%) and the average period between initial treatment and resolution of SRD was 11 months (range 2-18 months). The average number of SRT irradiation until resolution of SRD was 2.6 times (range 1-5 times). In the other 5 eyes, SRD was decreased after every SRT but didn't disappear by multiple treatments.

Conclusions : SRT may promote absorption of subretinal fluid and maintenance of BCVA for TDS. The resolution of SRD was achieved in half of the cases.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×